A Study of LY3295668 Erbumine in Participants With Relapsed/?Refractory Neuroblastoma
- Conditions
- euroblastomaTherapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2024-512102-25-00
- Lead Sponsor
- Eli Lilly & Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 1
Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue. Participants must be able to submit an archival sample of tissue., Participants must be able to swallow capsules.
Participants must not have had an allogeneic hematopoietic stem cell, bone marrow, or solid organ transplant., Participants must not have untreated tumor that has spread to the brain or spinal cord., Participants must not have a serious active disease other than neuroblastoma., Participants must not have a condition affecting absorption., Participants must not have had prior aurora kinase inhibitor exposure., Participants must not have a known allergy to the study treatment., Participants must not have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method